CN104352461A - Oral pharmaceutical preparation of tadalafil - Google Patents
Oral pharmaceutical preparation of tadalafil Download PDFInfo
- Publication number
- CN104352461A CN104352461A CN201410563329.9A CN201410563329A CN104352461A CN 104352461 A CN104352461 A CN 104352461A CN 201410563329 A CN201410563329 A CN 201410563329A CN 104352461 A CN104352461 A CN 104352461A
- Authority
- CN
- China
- Prior art keywords
- tadanafil
- tadalafil
- preparation
- oral
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an oral pharmaceutical preparation of tadalafil, and application of the preparation on treating male erectile dysfunction. The oral pharmaceutical preparation is characterized in that the basic remedy is tadalafil or a salt thereof, wherein the specific dosage form of the preparation is an orally disintegrating tablet, a chewable tablet or an oral membrane preparation and other preparations capable of being released quickly in the oral cavity. Tadalafil is a slightly-soluble drug with relatively low bioavailability, so that the invalid dosage is relatively high, the drug can generate multiple adverse reactions, and the unreasonable prescription can cause visual impairment or visual loss. The research of the pharmaceutical preparation of tadalafil on increasing the bioavailability of the drug and reducing the adverse reactions is very important for wide application of tadalafil on treatment of male sexual dysfunction clinically. Secondly, through improvement on the compliance of the pharmaceutical preparation of tadalafil when a patient takes the drug, especially takes the drug in a non-swallowing manner in a water-free environment, the oral pharmaceutical preparation is a boon for a lot of ED (Erectile Dysfunction) patients. The oral pharmaceutical preparation of tadalafil disclosed by the invention is patient oriented, and produced through a large number of researches.
Description
Technical field
The present invention relates to the oral drug preparation of tadanafil, and the application in treatment male erectile dysfunction.
Background technology
Tadanafil (Tadalafil), trade name rhinoceros man of great strength (Cialis), for reversible, selectivity phosphodiesterase 5 inhibitor (PDE5), treatment male erectile dysfunction (ED) is developed by Li Lai company, November 23 in 2003, Nikkei FDA approval listing, was also the 3rd new drug for ED of FDA approval.The concrete mechanism of action of tadanafil is: nitric oxide (NO) is the main medium causing corpus cavernosal smooth muscle to relax and erect.Tadanafil is phosphodiesterase (PDE) V selective depressant, can strengthen NO under sexual stimulus and discharge the erection physiological reaction caused.NO discharges and the receptors bind corpus cavernosal smooth muscle from teleneuron and endotheliocyte, sGC in active cell, the latter is under Mn2+ participates in, GTP (guanosine triphosphate) (GTP) is impelled to become cGMP (cGMP), cGMP activated protein kinase G (PKG) and fraction protein kinase A (PKA), PKG and PKA activated makes Intracellular signaling level reduce by activation Ca2+ pump, thus cause corpus cavernosal smooth muscle to relax, arterial blood flows into, and penis is congested, hard, erection.In human corpus cavernosum tissue and vascular smooth muscle, there is PDE V, cGMP can be made to be hydrolyzed to GMP, block the NO-cGMP approach making erection.Tadanafil is PDE V selective depressant, can prevent the degraded of cGMP, thus can strengthen the erection reaction of sexual excitation.
Tadanafil, be used to treat erection disturbance, listing preparation is tablet, for a kind of general thin coated tablet, this product contains tadanafil and following non-active ingredient: cross-linking sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, ferrum oxide, lactose monohydrate, magnesium stearate, microcrystalline Cellulose, sodium lauryl sulfate, Pulvis Talci, titanium dioxide and glyceryl triacetate.See FDA official website publish information.
Tadanafil is insoluble drug, and bioavailability is lower, and the ineffective dose therefore taken is larger, and can produce multiple bad putting and answer, non-rational use of drug can cause vision impairment or forfeiture.Pharmaceutical preparation for tadanafil is improving the bioavailability of medicine, reduces the research of the generation of untoward reaction, is widely used in treatment male sexual disorder clinically particularly important for tadanafil.Secondly, for the raising of the compliance of pharmaceutical preparation when patient takes of tadanafil, taking especially in non-mode of swallowing under anhydrous environment is very large Gospel concerning numerous ED patient.
The present invention is this just with patient, produces through large quantity research.
Summary of the invention
We are in the favorite outer discovery of research for tadanafil, tadanafil can direct oral cavity mucosal absorption to blood, corresponding report is had no through retrieval, the preparation mainly thin membrane coated tablet of tadanafil prepared by currently available technology, directly swallowed into stomach with water in the oral cavity, do not have the release of active substance, other gastrointestinal administration preparations containing tadanafil reported are all less than the Absorption Study data at the position, oral cavity for tadanafil.
The pharmacokinetic trial that the tadanafil direct oral cavity that the present invention includes absorbs:
Get rat 10, be divided into 2 groups at random, one group of 5 female Mus, one group of 5 male Mus.Adopt ether inhalation by rat anesthesia, cut the long opening of 1cm with after skin under 75% ethanol disinfection neck, peel away the tissue such as subcutaneous fat and muscle with tweezers, confirm esophagus and use stitching thread ligation, skin suture immediately.After ligation operation, 30min gives tadanafil.First powdery tadanafil is added not containing after mixing in tadanafil toothpaste by 0.2% amount, by 1mg/g(BW) [be equivalent to tadanafil 2mg/kg(BW)] give in the rat oral cavity of esophagus ligation, after 10min, rinse the toothpaste residue in oral cavity with water.Difference blood sampling half an hour (extract eyeball and get blood 1ml) after administration, centrifugal 3000rpm, 5min,-20 DEG C of preservations, take Liquid Chromatography/Mass Spectrometry (having a detailed description below) to measure the blood drug level of tadanafil, result is unexpected, and meansigma methods reaches 10ng/ml unexpectedly.
Further, in order to the accident of proved scheme finds, we choose health adult male 10, in oral cavity, buccal is about the above-mentioned toothpaste containing 0.2% tadanafil of 2g, do not swallow within 1 minute, afterwards the toothpaste containing tadanafil is all spued, and gargle with water, be collected in unified container, and measure the content of the Ta Dalafeng in this container, found that, the content of the Ta Dalafeng that can only be recovered to only has about 70 ~ 80% before administration, is surprised to find the 1 minutes buccal absorption tadanafil of about 20%.Concrete data are as shown in the table:
For the above-mentioned unexpected medicine found for absorption data, we further developed the oral drug preparation that can discharge rapidly in the oral cavity, are exactly oral cavity disintegration tablet, chewable tablet and pelliculae pro cavo oris specifically.
Through retrieval, existing patent report tadanafil oral disintegrating tablet formulation (application number: 201210236261.4), disclose the general prescription composition of tadanafil oral cavity disintegration tablet, and particularly point out composition is in this patent:
Principal agent tadanafil 15 ~ 20%
Polyvinyl pyrrolidone (PVP) 10 ~ 15%
Filler mannitol 40 ~ 80%
Fluidizer magnesium stearate 1 ~ 2%
Effervescent citric acid/sodium bicarbonate 3 ~ 10%
And be the preparation being realized tadanafil oral cavity disintegration tablet by the method for spray-drying process tabletting again.We are finding after a large amount of experimentatioies, the method of the wet granulation of the higher more convenient operation of industrialization level can be taked completely, key operation is added by the mode of interior additional combination when always mixing by disintegrating agent, optimization formulation forms and adds that the correctives improving mouthfeel prepares not only in the oral cavity can fater disintegration but also the pleasant tadanafil oral cavity disintegration tablet of mouthfeel, disintegration time is about 20 seconds, and it is better that random 10 volunteers attempt taking rear all expressions mouthfeel.
Concrete prescription consists of:
Tadanafil or its salt (in tadanafil) 1 ~ 20%
Disintegrating agent 5 ~ 20%
Binding agent 1 ~ 8%
Filler 50 ~ 80%
Correctives 0 ~ 5%
Lubricant 0 ~ 3%
More preferably, the preferred cross-linking sodium carboxymethyl cellulose of above-mentioned disintegrating agent, the preferred PVP K30 of binding agent, the preferred lactose of filler, the preferred Mint Essence of correctives, the preferred magnesium stearate of lubricant.
Such as:
Tadanafil or its salt (in tadanafil) 1 ~ 20%
Cross-linking sodium carboxymethyl cellulose 10 ~ 15%
PVP K30 2 ~ 5%
Lactose 65 ~ 75%
Mint Essence 1 ~ 4%
Magnesium stearate 1 ~ 2%
Through retrieval, (application number: 201210363306.4) discloses in this patent existing patent report tadanafil pelliculae pro cavo oris
The general prescription composition of tadanafil oral instant membrane:
Active constituents of medicine (tadanafil) 20 ~ 40%
Water soluble film-forming material 40 ~ 75%
Plasticizer 10 ~ 25%
Disintegrating agent 0 ~ 25%
Water 0.1% ~ 8%
According to the tadanafil oral instant membrane of above-mentioned prescription composition preparation, the effect of release fast all cannot be reached by many experiments, trace it to its cause, we know that tadanafil is insoluble drug, almost insoluble in water, so the tadanafil oral instant membrane causing above-mentioned prescription to form can not be instant.Lot of experiments research through us finds, the surfactant adding 1 ~ 5% in prescription can effectively solve this problem, we creatively add correctives and pigment on this basis, have prepared the tadanafil pelliculae pro cavo oris of the Gao Pinxiang of quick release.Concrete prescription consists of:
Tadanafil or its salt (in tadanafil) 20 ~ 40%
Water soluble polymer 45 ~ 65%
Plasticizer 0 ~ 20%
Correctives 0 ~ 5%
Surfactant 1 ~ 5%
Pigment 0 ~ 0.02%
Ethanol water 0.2 ~ 5%
More preferably, the feature of above-mentioned each component is, water soluble polymer is selected from one or more in polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), hyprolose (HPC), sodium carboxymethyl cellulose (CMC-Na), ethyl cellulose (EC) sodium alginate, pectin and amylose, preferably polyethylene alcohol; Plasticizer is selected from one or more in glycerol, propylene glycol, Polyethylene Glycol, phthalic acid ester, citron acid esters, glyceryl triacetate and Oleum Ricini, preferred Polyethylene Glycol; Correctives is selected from one or more in sucrose, mannitol, aspartame, Mint Essence, cherry essence, steviosin, preferred Mint Essence; Surfactant is selected from anion surfactant, preferably sodium dodecyl sulfate; Pigment is selected from common food coloring, preferred sunset yellow.
Such as:
Tadanafil or its salt (in tadanafil) 20 ~ 40%
Polyvinyl alcohol 50 ~ 60%
Polyethylene Glycol 5 ~ 15%
Mint Essence 1 ~ 4%
Sodium lauryl sulphate 2 ~ 4%
Sunset yellow 0 ~ 0.02%
Ethanol water 2 ~ 4%
The realization of above-mentioned tadanafil pelliculae pro cavo oris, also comprises preparation method:
(1) River Bank Stability: be dissolved or dispersed in the mixed solution of second alcohol and water by adjuvants such as medicine and macromolecule high polymers, is incubated and continuous stirring after obtained uniform serosity, dissolves, obtain even, bubble-free serosity at 60 DEG C;
(2) dried coating film: medicine is starched curtain coating on the plastic cover of plastic-coated wrapping paper, medicine slurry enters drying baker drying together with wrapping paper;
(3) cut film packaging: the small pieces being cut into 20mm*30mm by Roll-turning tool, then be packaged to be finished product through hot press heat seal.
Above-mentioned tadanafil oral cavity disintegration tablet and pelliculae pro cavo oris can realize tadanafil partially absorbing in the oral cavity, thus avoid the first pass effect of part tadanafil.Also improve the clinical compliance taken of existing conventional tablet to a certain extent, can take in anhydrous situation, and conveniently swallow.More preferably; we find tadanafil to be prepared into chewable tablet; except reaching these effects above-mentioned; some advantage is the privacy protecting patient highlightedly in addition; the patient of sexual dysfunction is taken to chew ground mode inadvertently; should not cause other people discovering, this point is significant beyond doubt to patient.
After prescription is groped, we find that the tadanafil chewable tablet that following formula preparation obtains can realize above-mentioned effect:
Tadanafil or its salt (in tadanafil) 1 ~ 20%
Disintegrating agent 0 ~ 10%
Binding agent 3 ~ 10%
Filler 55 ~ 90%
Correctives 0 ~ 5%
Lubricant 0 ~ 3%
More preferably, the preferred cross-linking sodium carboxymethyl cellulose of above-mentioned disintegrating agent, the preferred PVP K30 of binding agent, the preferred lactose of filler, the preferred Mint Essence of correctives, the preferred magnesium stearate of lubricant.
Such as:
Tadanafil or its salt (in tadanafil) 1 ~ 20%
Cross-linking sodium carboxymethyl cellulose 2 ~ 5%
PVP K30 3 ~ 5%
Lactose 65 ~ 85%
Mint Essence 1 ~ 4%
Magnesium stearate 1 ~ 2%
The preparation method of the present invention's also claimed a kind of tadanafil chewable tablet:
(1) in prescription ratio, accurately take part supplementary material (principal agent, binding agent, filler and disintegrating agent), cross 100 mesh sieves, thoroughly mix, the appropriate amount of ethanol adding 50% prepares soft material, granulates with 24 mesh sieves, 60 DEG C of dryings, then uses 24 mesh sieve granulate.
(2) add correctives and lubricant in the granule after above-mentioned granulate, abundant mix homogeneously, tab weight, tabletting, to obtain final product.
Separately through retrieval, existing patent report tadalafil chewing gum preparation (application number: 200610010529.7), it also mentions this preparation in the description can mention raising bioavailability, but do not have its mechanism clear and definite, and be not difficult to know as pharmacy worker, chewing gum is not a kind of active drug preparation of Clinical practice, in addition, tadanafil is a kind of insoluble drug, is difficult to discharge completely, is unfavorable for that it is medicinal in chewing gum base.Therefore, this invention can not impact the novelty of the medicinal chewable tablet of tadanafil of the present invention and creativeness.
The creativeness that the present invention surprisingly brings is: substantially increase the compliance of this medicine when Clinical practice, just the process taken can be completed smoothly under anhydrous environment, and there is splendid mouthfeel, oral cavity fresh and cool is sweet, serves beyond thought effect to a certain extent in treatment male sexual disorder.In addition, improve the bioavailability of tadanafil to a certain extent.
For further illustrating effect of the present invention, our contrived experiment, contrasts the situation of bioavailability of conventional tablet of tadanafil oral cavity disintegration tablet of the present invention, chewable tablet and pelliculae pro cavo oris and tadanafil.
Medicine: tadalafil tablet (Xi Aili) specification: 20mg lot number: A928623
Tadanafil oral cavity disintegration tablet (self-control) specification: 20mg lot number: 20120401
Tadanafil chewable tablet (self-control) specification: 20mg lot number: 20120501
Tadanafil pelliculae pro cavo oris (self-control) specification: 20mg lot number: 20120601
Experimenter:
Select 20 volunteer the tested ages 19-30 year healthy male, non-smoking history, does not take other medicines during 7 days and whole research before taking medicine.
Grouping and administration:
20 experimenters are divided into 4 groups at random, often organize 5 people, often organize a kind that takes at random in above-mentioned 4 kinds of tadanafil preparations.Observed and recorded sign at any time after taking medicine, before contrast is taken medicine and take medicine one week blood and hepatic and renal function index afterwards, finally takes medicine and also needs to follow up a case by regular visits to two weeks.
Sample collecting:
Before administration with administration after 0.5,1,2,3,4,12,24,48,72 and 120 hr iv get blood 5ml, centrifugal 3000rpm, 5min ,-20 DEG C of preservations
Sample detection (Liquid Chromatography/Mass Spectrometry):
A chromatographic condition: Luna phenyl-hexyl chromatographic column (4.6mm*100mm, 5pm); Column temperature: room temperature; Mobile phase: methanol-water (10:90); Flow: 1.0mL/min; Sample size 35ul.
B Mass Spectrometry Conditions: Atmosphere Pressure Chemical Ionization (APCI).Detection mode is that cation detects, heated atomizer temperature 500 DEG C; Multiplier voltage: 2000V; Collision voltage: 22V; The mass-to-charge ratio detecting ion is tadanafil 390.1-268.2; Interior mark 394.1-272.2; Residence time is respectively 350,150ms.
The pretreatment of c blood sample: add 10ng/ml inner mark solution 1ml in blood serum sample, mixing, is transferred to solid-phase extracting disk, and low speed is about 0.2ml/min suction; Use methanol-water (15:85) 1ml and methanol-water (90:10) 150uL eluting successively, collect 2 eluents, concussion 1min; The centrifugal 5min of 3000rpm, gets supernatant sample introduction.Measured value calculates the blood drug level of tadanafil by pre-rendered standard curve and calculates relevant parameter.
D testing result, the contrast table of pharmacokinetic parameter
| Parameter name | Xi Aili sheet | Oral cavity disintegration tablet | Chewable tablet | Pelliculae pro cavo oris | p |
| Cmax（ng.ml -1) | 164(23.1) | 201(26.7) | 209(28.7) | 197(29.3) | <0.01 |
| Tmax（h） | 3(1.0-4.0) | 4(1.0-4.0) | 4(1.0-4.0) | 3(1.0-4.0) | >0.05 |
| Ke(h -1） | 0.0368 | 0.0371 | 0.0374 | 0.0369 | >0.05 |
| T 1/2b(h) | 18.6(12.6-34.5) | 18.2(10.8-31.3) | 18.5(11.2-33.4) | 18.3(12.9-35.7) | >0.05 |
| AUC 0-t（ng.h.ml -1) | 3790(35.3) | 4810(33.6) | 4870(32.1) | 4830(34.5) | <0.01 |
| AUC 0-∞（ng.h.ml -1) | 3920(35.3) | 4880(33.6) | 4930(32.1) | 4890(34.5) | <0.01 |
| CL/F(L.h -1) | 2.79(30.7) | 2.81(29.2) | 2.82(31.0) | 2.77(29.4) | >0.05 |
| V/F(L) | 73.3(20.1) | 73.7(25.8) | 72.1(23.9) | 71.2(22.2） | >0.05 |
E data analysis: the Xi Aili sheet of the oral cavity disintegration tablet of tadanafil, chewable tablet and pelliculae pro cavo oris and prior art is equally equal can be absorbed effectively quickly, keeps higher blood drug level (T for a long time
1/2b>18 hour).But the dosage form tadanafil absorptance of oral cavity disintegration tablet, chewable tablet and pelliculae pro cavo oris comparatively completely (Cmax, AUC, p<0.01).
Detailed description of the invention
Provide embodiment representative in following the present invention so that content of the present invention to be described, but be not intended in office where face limits the present invention.Namely tadanafil in embodiment refers to tadanafil or its salt, the amount average w/v (w/v) provided, and is the amount based on tadanafil.
, according to patent 201210236261.4 prepare tadanafil oral cavity disintegration tablet
prescription: 1000
| Tadanafil | 100g | 10.0% |
| Polyvinylpyrrolidone (PVP) | 125g | 12.5% |
| Mannitol | 700g | 70% |
| Magnesium stearate | 15g | 1.5% |
| Citric acid | 30g | 3% |
| Sodium bicarbonate | 30g | 3% |
preparation method:
(1) tadanafil, binding agent, filler are dissolved in acetone, are called a, b, c solution, citric acid is dissolved in b solution, sodium bicarbonate is dissolved in c solution.
(2) a solution is first carried out spraying dry, make medicine be after " boiling " state, then spray into b and c solution successively, dry, obtain the solids in Powdered or microparticle shape.
(3) solids (2) obtained mixes with residue adjuvant, and intermediates content mixes with magnesium stearate, tabletting after detecting.
Tadalafil tablet operation is prepared loaded down with trivial details according to above-mentioned formulation and technology, and the extremely difficult realization of spray-drying process, organic solvents-acetone is residual comparatively serious.
, tadanafil oral cavity disintegration tablet 20mg
prescription: 1000
| Tadanafil | 20g | 10.0% |
| Carboxymethyl starch sodium | 27g | 13.5% |
| Hydroxypropyl methylcellulose | 10g | 5.0% |
| Mannitol | 140g | 70.0% |
| Aspartame | 1g | 0.5% |
| Pulvis Talci | 2g | 1.0% |
operational approach:
(1) in prescription ratio, accurately take part supplementary material (disintegrating agent of principal agent, binding agent, filler and half), cross 100 mesh sieves, thoroughly mix, the appropriate amount of ethanol adding 50% prepares soft material, granulates with 24 mesh sieves, 60 DEG C of dryings, then uses 24 mesh sieve granulate.
(2) add correctives and lubricant and second half disintegrating agent in the granule after above-mentioned granulate, abundant mix homogeneously, tab weight, tabletting, to obtain final product.
, tadanafil oral cavity disintegration tablet 10mg
prescription: 1000
| Tadanafil | 10g | 5.0% |
| Polyvinylpolypyrrolidone | 27g | 13.5% |
| Hydroxypropyl cellulose | 10g | 5.0% |
| Sucrose | 150g | 75.0% |
| Steviosin | 1g | 0.5% |
| Magnesium stearate | 2g | 1.0% |
operational approach: with embodiment 2
4, tadanafil oral cavity disintegration tablet 20mg
prescription: 1000
| Tadanafil | 20g | 10.0% |
| Cross-linking sodium carboxymethyl cellulose | 25g | 12.5% |
| PVP K30 | 8g | 4.0% |
| Lactose | 140g | 70.0% |
| Mint Essence | 4g | 2.0% |
| Magnesium stearate | 3g | 1.5% |
operational approach: with embodiment 2
5, tadanafil oral cavity disintegration tablet 10mg
prescription: 1000
| Tadanafil | 10g | 5.0% |
| Cross-linking sodium carboxymethyl cellulose | 26g | 13.0% |
| PVP K30 | 8g | 4.0% |
| Lactose | 150g | 75.0% |
| Mint Essence | 4g | 2.0% |
| Magnesium stearate | 2g | 1.0% |
operational approach: with embodiment 2
6, the detection of embodiment 1-5 sample: be placed in 2ml water, measure time and the mouthfeel of complete disintegrate, result is as follows
| Disintegration time (s) | Mouthfeel | |
| Embodiment 1 | 18 | Tasteless |
| Embodiment 2 | 16 | Taste is sweet |
| Embodiment 3 | 15 | Taste is sweet |
| Embodiment 4 | 13 | Taste is sweet and pure and fresh |
| Embodiment 5 | 12 | Taste is sweet and pure and fresh |
7, according to tadanafil pelliculae pro cavo oris prepared by patent 201210363306.4
prescription:
| Tadanafil | 100g | 34.6% |
| Polyvinyl alcohol 1788 | 133g | 46.0% |
| PEG400 | 33g | 11.4% |
| Sodium alginate | 13g | 4.5% |
| Purified water | 10g | 3.5% |
operational approach:
First join in purified water by the polyvinyl alcohol of above-mentioned amount under stirring, water-bath is dissolved, and obtains coagulant liquid, then adds PEG400, sodium alginate, stirring and dissolving.By the solution left standstill for preparing or ultrasonic removing bubble, the tadanafil of recipe quantity is added above-mentioned solution, stir, tadanafil is dispersed in solution.Dissolution homogeneity is coated 3*10cm
2corrosion resistant plate, dry 2 hours of 40-60 DEG C of blast heating.Demoulding, by 2*3cm
2size cut, obtain the tadanafil pelliculae pro cavo oris that content of dispersion is 20mg/ sheet.
The tadanafil pelliculae pro cavo oris oral absorption prepared according to above-mentioned formulation and technology is bad, and mouthfeel is more pained.
, tadanafil pelliculae pro cavo oris
prescription: 1000
| Tadanafil | 100g | 33.7% |
| Polyvinyl alcohol 1788 | 133g | 44.8% |
| PEG400 | 33g | 11.1% |
| Sodium alginate | 13g | 4.4% |
| Aspartame | 3g | 1.0% |
| Tween 80 | 5g | 1.7% |
| Sunset yellow | 0.05g | 0.017% |
| Ethanol water | 10g | 3.4% |
operational approach:
(1) River Bank Stability: be dissolved or dispersed in the mixed solution of second alcohol and water by adjuvants such as medicine and macromolecule high polymers, is incubated and continuous stirring after obtained uniform serosity, dissolves, obtain even, bubble-free serosity at 60 DEG C;
(2) dried coating film: medicine is starched curtain coating on the plastic cover of plastic-coated wrapping paper, medicine slurry enters drying baker drying together with wrapping paper;
(3) cut film packaging: the small pieces being cut into 20mm*30mm by Roll-turning tool, then be packaged to be finished product through hot press heat seal.
, tadanafil pelliculae pro cavo oris
prescription: 1000
| Tadanafil | 100g | 33.7% |
| Polyvinyl alcohol 1788 | 133g | 44.8% |
| PEG400 | 33g | 11.1% |
| Sodium alginate | 13g | 4.4% |
| Mint Essence | 3g | 1.0% |
| Sodium lauryl sulphate | 5g | 1.7% |
| Sunset yellow | 0.05g | 0.017% |
| Ethanol water | 10g | 3.4% |
operational approach: with embodiment 8
10, the detection of embodiment 7-9 sample:
Be placed in the 100ml beaker that 100ml water is housed, measure membrane consoluet time and mouthfeel under 37 DEG C of water bath with thermostatic control magnetic agitation (100rpm), result is as follows
| Disintegration time (s) | Mouthfeel | |
| Embodiment 7 | 58 | Bitter taste |
| Embodiment 8 | 46 | Taste is sweet |
| Embodiment 9 | 43 | Taste is sweet and pure and fresh |
11, tadanafil chewable tablet 20mg
prescription: 1000
| Tadanafil | 20g | 10.0% |
| Carboxymethyl starch sodium | 10g | 5.0% |
| PVP K30 | 18g | 9.0% |
| Microcrystalline Cellulose | 150g | 75.0% |
| Orange flavor | 1g | 0.5% |
| Pulvis Talci | 1g | 0.5% |
operational approach:
(1) in prescription ratio, accurately take part supplementary material (principal agent, binding agent, filler and disintegrating agent), cross 100 mesh sieves, thoroughly mix, the appropriate amount of ethanol adding 50% prepares soft material, granulates with 24 mesh sieves, 60 DEG C of dryings, then uses 24 mesh sieve granulate.
(2) add correctives and lubricant in the granule after above-mentioned granulate, abundant mix homogeneously, tab weight, tabletting, to obtain final product.
, tadanafil chewable tablet 5mg
prescription: 1000
| Tadanafil | 5g | 2.5% |
| Polyvinylpolypyrrolidone | 12g | 6.0% |
| Hydroxypropyl cellulose | 15g | 7.5% |
| Pregelatinized Starch | 165g | 82.5% |
| Aspartame | 1g | 0.5% |
| Pulvis Talci | 2g | 1.0% |
operational approach: with embodiment 11
13, tadanafil chewable tablet 20mg
prescription: 1000
| Tadanafil | 20g | 10.0% |
| Cross-linking sodium carboxymethyl cellulose | 8g | 4.0% |
| PVP K30 | 8g | 4.0% |
| Lactose | 155g | 77.5% |
| Mint Essence | 6g | 3.0% |
| Magnesium stearate | 3g | 1.5% |
operational approach: with embodiment 11
14, tadanafil chewable tablet 10mg
prescription: 1000
| Tadanafil | 10g | 5.0% |
| Cross-linking sodium carboxymethyl cellulose | 8g | 4.0% |
| PVP K30 | 8g | 4.0% |
| Lactose | 165g | 82.5% |
| Mint Essence | 6g | 3.0% |
| Magnesium stearate | 3g | 1.5% |
operational approach: with embodiment 11
15, tadanafil chewable tablet 5mg
prescription: 1000
| Tadanafil | 5g | 2.5% |
| Cross-linking sodium carboxymethyl cellulose | 9g | 4.5% |
| PVP K30 | 9g | 4.5% |
| Lactose | 168g | 84% |
| Mint Essence | 5g | 2.5% |
| Magnesium stearate | 4g | 2.0% |
operational approach: with embodiment 11
16, the detection of embodiment 11-15 sample
Select at random 12 healthy, without the 20-40 year volunteer of the bad habit such as smoking, excessive drinking, men and women half and half, gets the chewable tablet of different embodiment for volunteer oral, spues after chewing 10s at every turn, and gargle for several times with warm water, select immediate mouthfeel according to following scoring criterion and give a mark, removing a best result and one minimum point, often group marking result is the meansigma methods of 10 volunteers, score value is higher, and mouthfeel is better.
Mouthfeel scoring criterion:
| With or without sand type | Mouth feel score | |
| Embodiment 11 | Have | 6.5 |
| Embodiment 12 | Slightly | 7.2 |
| Embodiment 13 | Nothing | 9.5 |
| Embodiment 14 | Nothing | 9.2 |
| Embodiment 15 | Nothing | 9.1 |
Taste is sweet in sand type: 8-10 divides; Taste sweet grittiness sense 6-7 divides; Tastelessly to divide without sand type 3-5; Tasteless grittiness sense 0-3 divides.
Claims (7)
1. oral drug preparation, it is characterized in that principal agent is tadanafil or its salt, concrete dosage form is chewable tablet preparation.
2. according to claim 1, the principal agent of tadanafil described in it or its salt, is characterized in that, is rapidly absorbed by oral mucosa at position, oral cavity.
3. according to claim 1, chewable tablet described in it, is characterized in that, each Ni lead-free solder alloy is:
Tadanafil or its salt (in tadanafil) 1 ~ 20%
Disintegrating agent 0 ~ 10%
Binding agent 3 ~ 10%
Filler 55 ~ 90%
Correctives 0 ~ 5%
Lubricant 0 ~ 3%.
4. according to claim 3, the preferred cross-linking sodium carboxymethyl cellulose of disintegrating agent described in it, the preferred PVP K30 of binding agent, the preferred lactose of filler, the preferred Mint Essence of correctives, the preferred magnesium stearate of lubricant.
5., according to the chewable tablet of claim 3,4, preferred prescription composition is:
Tadanafil or its salt (in tadanafil) 1 ~ 20%
Cross-linking sodium carboxymethyl cellulose 2 ~ 5%
PVP K30 3 ~ 5%
Lactose 65 ~ 85%
Mint Essence 1 ~ 4%
Magnesium stearate 1 ~ 2%.
6., according to the preparation method of the chewable tablet of claim 3,4 and 5, comprising:
(1) in prescription ratio, accurately take part supplementary material (principal agent, binding agent, filler and disintegrating agent), cross 100 mesh sieves, thoroughly mix, the appropriate amount of ethanol adding 50% prepares soft material, granulates with 24 mesh sieves, 60 DEG C of dryings, then uses 24 mesh sieve granulate;
(2) add correctives and lubricant in the granule after above-mentioned granulate, abundant mix homogeneously, tab weight, tabletting, to obtain final product.
7. the application of oral drug preparation in treatment male erectile dysfunction according to claim 1-6, is characterized in that oral administration biaavailability is higher.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410563329.9A CN104352461B (en) | 2013-04-28 | 2013-04-28 | The oral drug preparation of Tadalafei |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310153588.XA CN103191075B (en) | 2013-04-28 | 2013-04-28 | Oral medicinal preparation of tadalafil |
| CN201410563329.9A CN104352461B (en) | 2013-04-28 | 2013-04-28 | The oral drug preparation of Tadalafei |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310153588.XA Division CN103191075B (en) | 2013-04-28 | 2013-04-28 | Oral medicinal preparation of tadalafil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104352461A true CN104352461A (en) | 2015-02-18 |
| CN104352461B CN104352461B (en) | 2017-07-14 |
Family
ID=52519838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410563329.9A Active CN104352461B (en) | 2013-04-28 | 2013-04-28 | The oral drug preparation of Tadalafei |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352461B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1472210A (en) * | 2002-08-02 | 2004-02-04 | 路德让 | Compound for treating sexual dysfunction |
| WO2009074995A1 (en) * | 2007-12-10 | 2009-06-18 | Ajanta Pharma Limited | Taste masked chewable compositions of sildenafil citrate |
| CN101754755A (en) * | 2007-02-15 | 2010-06-23 | 德尔玛-杨有限公司 | Compositions and methods for enhancing transmucosal delivery |
| WO2011030351A2 (en) * | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
-
2013
- 2013-04-28 CN CN201410563329.9A patent/CN104352461B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1472210A (en) * | 2002-08-02 | 2004-02-04 | 路德让 | Compound for treating sexual dysfunction |
| CN101754755A (en) * | 2007-02-15 | 2010-06-23 | 德尔玛-杨有限公司 | Compositions and methods for enhancing transmucosal delivery |
| WO2009074995A1 (en) * | 2007-12-10 | 2009-06-18 | Ajanta Pharma Limited | Taste masked chewable compositions of sildenafil citrate |
| WO2011030351A2 (en) * | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104352461B (en) | 2017-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103191075B (en) | Oral medicinal preparation of tadalafil | |
| AU2006220100B2 (en) | Pharmaceutical forms with improved pharmacokinetic properties | |
| JP5859664B2 (en) | Oral pharmaceutical composition with masked taste of drug and method for producing the same | |
| JP6827923B2 (en) | Dexamethasone Oral Film | |
| CN104168895A (en) | High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient | |
| CA2984615C (en) | Vortioxetine pyroglutamate | |
| KR101304343B1 (en) | Fast dissolving oral formulation of pde-5 inhibitors | |
| CN103974695A (en) | Bitter taste masked oral thin film formulation of sildenafil citrate | |
| CN104902928B (en) | Include the total micronizing product of uliprista acetate | |
| CN105362240A (en) | Orally disintegrating tablet | |
| KR20190089892A (en) | Oral disintegrating tablets containing diamine derivatives | |
| BRPI0513938B1 (en) | pharmaceutical composition containing drospirenone and ethinyl estradiol | |
| JP6417480B2 (en) | Tadalafil oral disintegration film and method for producing the same | |
| CN101683324A (en) | Oral disintegrative tablet of sildenafil citrate and preparation method thereof | |
| KR102239291B1 (en) | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof | |
| WO2011136751A2 (en) | Water soluble pharmaceutical composition | |
| KR20130135611A (en) | Bitter taste masked oral pharmaceutical composition comprising pde-5 inhibitor | |
| JPH11310539A (en) | Intraoral-disintegrative type composition and its production | |
| WO2019151405A1 (en) | Tablets and method for producing same | |
| CN104352461A (en) | Oral pharmaceutical preparation of tadalafil | |
| CN104274417A (en) | Oral drug preparation of tadalafil | |
| CN103860499A (en) | Methadone hydrochloride orally disintegrating tablet and preparation method thereof | |
| RU2276982C2 (en) | Agent possessing with anti-inflammatory, analgesic and antipyretic effect as tablet | |
| TW202216123A (en) | Formulations | |
| CN115154429A (en) | Tadalafil oral disintegrating composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 903 room 5 Applicant after: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: The Science Park 211100 Nanjing Road, Jiangsu province No. 18 Applicant before: NANJING HAIRONG PHARMACEUTICAL TECHNOLOGY CO.,LTD. |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oral medicinal preparation of tadalafil Effective date of registration: 20190924 Granted publication date: 20170714 Pledgee: Nanjing Bank Co.,Ltd. Chengnan Branch Pledgor: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Registration number: Y2019320000152 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230210 Granted publication date: 20170714 Pledgee: Nanjing Bank Co.,Ltd. Chengnan Branch Pledgor: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Registration number: Y2019320000152 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |